{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(Suppl 1)"],"submitter":["Boyer M"],"funding":["Merck Sharp &amp; Dohme, a subsidiary of Merck &amp; Co., Inc.","Incyte Corporation"],"pubmed_abstract":["<h4>Background</h4>The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxygenase 1 (IDO1), an enzyme involved in kynurenine production, inhibits immune responses. Inhibition of IDO1 may restore antitumor immunity and augment CPI activity. This trial evaluated addition of epacadostat, a potent and highly selective IDO1 inhibitor, to pembrolizumab and chemotherapy for metastatic NSCLC.<h4>Methods</h4>ECHO-306/KEYNOTE-715 was a partial double-blind, randomized phase II study of adults with treatment-naïve stage IV NSCLC not indicated for EGFR-, ALK-, or ROS1-directed therapy. Patients were randomized to one of three treatme"],"journal":["BMC cancer"],"pagination":["1250"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11270757"],"repository":["biostudies-literature"],"pubmed_title":["Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study."],"pmcid":["PMC11270757"],"pubmed_authors":["Samkari A","Hui R","Munteanu MC","Su WC","Leopold L","Daniel J","Abreu DR","Clingan P","Urban D","Luo Y","Boyer M","Garassino M","Devaux C","Gadgeel S"],"additional_accession":[]},"is_claimable":false,"name":"Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.","description":"<h4>Background</h4>The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxygenase 1 (IDO1), an enzyme involved in kynurenine production, inhibits immune responses. Inhibition of IDO1 may restore antitumor immunity and augment CPI activity. This trial evaluated addition of epacadostat, a potent and highly selective IDO1 inhibitor, to pembrolizumab and chemotherapy for metastatic NSCLC.<h4>Methods</h4>ECHO-306/KEYNOTE-715 was a partial double-blind, randomized phase II study of adults with treatment-naïve stage IV NSCLC not indicated for EGFR-, ALK-, or ROS1-directed therapy. Patients were randomized to one of three treatme","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-05-29T11:56:43.591Z","creation":"2026-04-08T04:37:26.564Z"},"accession":"S-EPMC11270757","cross_references":{"pubmed":["39054462"],"doi":["10.1186/s12885-022-10427-4"]}}